Scarica l'app Stockscreener
13.24
3.15%
-0.43
Dopo l'orario di chiusura:
13.17
-0.07
-0.53%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARQT Giù?
Forum
Previsione
Precedente Chiudi:
$13.67
Aprire:
$13.7
Volume 24 ore:
1.64M
Relative Volume:
0.81
Capitalizzazione di mercato:
$1.55B
Reddito:
$59.61M
Utile/perdita netta:
$-262.14M
Rapporto P/E:
-3.3776
EPS:
-3.92
Flusso di cassa netto:
$-247.49M
1 W Prestazione:
-4.40%
1M Prestazione:
-4.95%
6M Prestazione:
+31.48%
1 anno Prestazione:
+125.55%
Intervallo 1D:
$13.16
$13.85
Intervallo di 1 settimana:
$13.16
$15.09
Portata 52W:
$5.38
$16.20
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Nome
Arcutis Biotherapeutics Inc
Settore
Industria
Telefono
805-418-5006
Indirizzo
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Confronta ARQT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
13.24 | 1.55B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-28 | Iniziato | Jefferies | Buy |
| 2024-01-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-10-26 | Downgrade | Mizuho | Buy → Neutral |
| 2023-10-13 | Downgrade | Goldman | Buy → Neutral |
| 2022-09-07 | Iniziato | Needham | Buy |
| 2022-03-17 | Iniziato | Goldman | Buy |
| 2021-06-30 | Iniziato | Mizuho | Buy |
| 2021-05-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-10-08 | Iniziato | Truist | Buy |
| 2020-02-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-02-25 | Iniziato | Cowen | Outperform |
| 2020-02-25 | Iniziato | Goldman | Neutral |
| 2020-02-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Arcutis Biotherapeutics Inc Borsa (ARQT) Ultime notizie
Short Interest in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Declines By 9.3% - MarketBeat
Recent 4.4% pullback isn't enough to hurt long-term Arcutis Biotherapeutics (NASDAQ:ARQT) shareholders, they're still up 118% over 1 year - Simply Wall St
(ARQT) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Are Medical Stocks Lagging Addus HomeCare (ADUS) This Year? - Yahoo Finance
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Up 6.8%Should You Buy? - MarketBeat
Arcutis Biotherapeutics to Present at Guggenheim SMID Cap Biotech Conference - StockTitan
Arcutis to Present at the Guggenheim SMID Cap Biotech Conference - The Manila Times
Zweig DiMenna Associates LLC Makes New Investment in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Arcutis Biotherapeutics: After Outstanding 2024, Shares May Face Cooling Off Period (ARQT) - Seeking Alpha
Objective long/short (ARQT) Report - Stock Traders Daily
HC Wainwright & Co. Initiates Coverage of Arcutis Biotherapeutics (ARQT) with Buy Recommendation - MSN
Short Interest in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Decreases By 9.3% - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 4%Time to Sell? - MarketBeat
Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 37.43%: Here's is How to Trade - MSN
Arcutis Biotherapeutics’ (ARQT) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Arcutis stock target lifted, buy rating held on significant developments By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap UpStill a Buy? - MarketBeat
Arcutis stock target lifted, buy rating held on significant developments - Investing.com India
Arcutis Biotherapeutics' (ARQT) Buy Rating Reiterated at HC Wainwright - MarketBeat
Demystifying Arcutis Biotherapeutics: Insights From 5 Analyst Reviews - Benzinga
JPMorgan Chase & Co. Raises Stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World
Arcutis Shares Climb on Strong Product Revenue Estimates - MarketWatch
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket - Benzinga
Biotech Stocks Facing FDA Decision In July 2024 - RTTNews
Arcutis Biotherapeutics, Inc. Announces Preliminary Unaudited Earnings Guidance for Fourth Quarter and Full Year 2024 - Marketscreener.com
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million - The Manila Times
Arcutis Q4 Revenue Surges 366% to $63M as ZORYVE Demand Accelerates Across Indications - StockTitan
Rajvir Madan Joins Arcutis as Chief Digital and Information Officer -June 01, 2021 at 07:30 am EDT - Marketscreener.com
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 8.5%Here's What Happened - MarketBeat
Commit To Purchase Arcutis Biotherapeutics At $7.50, Earn 21.3% Using Options - Nasdaq
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Expected to Rise, Mizuho Analyst Says - Defense World
High Growth Tech Stocks In The United States To Watch - Yahoo Finance
When the Price of (ARQT) Talks, People Listen - Stock Traders Daily
Mizuho Forecasts Strong Price Appreciation for Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Sets New 52-Week HighHere's What Happened - MarketBeat
Arcutis stock soars to 52-week high, hits $15.85 amid robust gains - Investing.com
Mizuho lifts Arcutis stock price target to $20, maintains Outperform By Investing.com - Investing.com Australia
Arcutis Biotherapeutics director Welgus sells $146,714 in stock By Investing.com - Investing.com Nigeria
Mizuho lifts Arcutis stock price target to $20, maintains Outperform - Investing.com
Insider Selling: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Director Sells 10,000 Shares of Stock - MarketBeat
Arcutis Biotherapeutics director Welgus sells $146,714 in stock - Investing.com
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Biotherapeutics Grants 75,500 RSUs to New Hires in Strategic Talent Acquisition Move - StockTitan
Here's Why Arcutis Stock More Than Doubled In Market Value In One Year - Barchart
Here's Why Arcutis Stock More Than Doubled in Market Value in One Year - MSN
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading 7% HigherHere's Why - MarketBeat
Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment? - Simply Wall St
Arcutis Biotherapeutics Inc Azioni (ARQT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):